National Centre for Asbestos Related Diseases

Publications

Further information

  • All current grants
  • All previous grants

Professional publications by our team members have been listed here.

You can contact individual team members to discuss their publications.

  1. 2015
  2. 2014
  3. 2013
  4. 2012
  5. 2011
  6. 2010
  7. 2009
  8. 2008
  9. 2007

2015

  • McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ and Robinson BW Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. European Journal of Immunology 2015 45 (1) 49-59
  • Johnson C, Saunders C, Phillips M, Emery J, Nowak AK, Overheu K, Ward A, Joske DJ Randomised controlled trial of a shared care model for cancer patients involving general practitioners and cancer specialists. Journal of Oncology Practice 2015  001569
  • Creaney J, Ma S, Sneddon SA, Tourigny MR, Dick IM, Leon JS, Khong A, Fisher SA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson MW, Robinson BW Strong spontaneous neo-antigen responses to tumours induced by a natural human carcinogen. OncoImmunology 2015 4(7) e1011492
  • Leong SL, Zainudin R, Kazan-Allen L, Robinson BW Asbestos in Asia Respirology 2015 20 549-55
    Steer HJ, Robinson BWS Axillary Crackles are more Prevalent than Basal Crackles in Asbestos Exposed Workers with Asbestosis  Jacobs Journal of Pulmonology 2015 1(1) 4-7
  • Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJN, Moses EK, Melton PE, deKlerk N, Musk AW, Robinson BWS, Creaney J Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma Gene 2015 1 103-5
    Creaney J, Robinson BWS Author's response: inconsistent results or inconsistent methods? A plea for standardisation ofbiomarker sampling in mesothelioma studies Thorax 2015 70 374-5
  • Creaney J, Dick IM, Robinson BWS Discovery of New Biomarkers for Malignant Mesothelioma Current Pulmomology Reports 2015 4 15-21
  • Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A, Lake RA Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations Scientific Reports 2015 5 12298
  • Creaney J, Dick IM, Robinson BW Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothlioma Current Opinion in Pulmonary Medicine 2015 21(4)  352-6
  • Hjerpe A, Ascoli V, Bedrossian CWM, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Onder S, Segal A, Vielh P Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma Acta Cytologia 2015 59(2) 2-16
  • Leong SL, Lee YCG, Robinson BW, Creaney J Role of Mesothelin measurement in Patients with Cytology-Negative Pleural Effusion undergoing Medical Thoracoscopy Pleura 2015  1-7
  • Lim CB, Prele CM, Baltic S, Arthur PG, Creaney J, Watkins DN, Thompson PJ, Mutsaers SE Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis Oncotarget 2015 6(3) 1519-30

Back to top

2014

  • Cleaver AL, Bhamidipaty K, Wylie B, Connor T, Robinson C, Robinson BW, Mutsaers SE, Lake RA Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance Carcinogenesis 2014 35 (2) 407-14
  • Robinson C, Woo S, Nowak AK, Lake RA Dietary Vitamin D supplementation does not reduce the incidence or severity of asbestos-induced mesothelioma in a mouse model Nutrition and Cancer 2014 66(3) 383-7
  • Williams AM, Bulsara CE, Joske DJL, Petterson AS, Nowak AK and Bennett KS An Oasis in the Hospital The Perceived Benefits of a Cancer Support Center in a Hospital Setting Offering Complementary Therapies Journal of Holistic Nursing 2014 3(20)
  • Nelson D, Fisher S, Robinson BW The “Trojan Horse” approach to tumor immunotherapy: targeting the tumour microenvironment. Journal of Immunology Research 2014 ID 78906
  • Hato SV, Khong A, De Vries IJM, Lesterhuis WJ Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics Clinical Cancer Research 2014 20 (11) 2831-7
  • Lesterhuis WJ, Nowak AK, Lake RA Immune stimulatory features of classical chemotherapy Cancer Immunotherapy (2nd ed) 2013 Ch 24 395-414
  • Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, Robinson BWS, Nowak AK, Lake RA Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans PLoS ONE 2014 e0103025
  • Creaney J, Dick IM, Meniawy TM, Leong S, Leon JS, Demelker Y, Segal A, Musk AW, Lee YCG, Skates SJ, Nowak AK and Robinson BWS Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma Thorax 2014 205205
  • Nowak A, Lesterhuis WJ Chemotherapy: still waiting for the magic to happen The Lancet Oncology 2014 15 780-1
  • Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, Robinson BWS, Nowak AK, Lake RA Effect of NSAIDS and COX-2 Inhibitors on the Incidence and Severity of Asbestos-Induced Malignant Mesothelioma: Evidence From an Animal Model and a Human Cohort Lung Cancer 2014 86 (1) 29-34
  • Lesterhuis WJ, Bosco A, Lake RA Comment on "Drug Discovery: Turning the Titanic" Science Translational Medicine 2014 6 (229) 229le2
  • McCoy MJ, Nowak AK, Lake RA Activation of Immune-Mediated Tumor Cell Death by Chemotherapy Cell Death in Biology and Diseases 2013 Chp14 373-99
  • Meniawy TM, Creaney J, Lake RA and Nowak AK Reply to Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’ British Journal of Cancer 2014 1-2
  • Armato III SG , Nowak AK, Francis RJ, Kocherginsky M, Byrne MJ Observer variability in mesothelioma tumor thickness measurements: Defining minimally measurable lesions Journal of Thoracic Oncology 2014 9, Iss 8 1187-1194
  • Fisher SA, Cleaver A, Lakiani DD, Khong A, Connor T, Wylie B, Lesterhuis WJ, Robinson BW, Lake RA Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. Journal of Translational Medicine 2014 12 (1) 245-54
  • Anyaegbu CC, Lake RA, Heel K, Robinson BW, Fisher SA Chemotherapy enhances cross-presentation of nuclear tumour antigens. PLoS ONE 2014 9 (9)
  • Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. Disease Markers 2014 Epub 23 Nov
  • Aston WJ, Fisher SA, Khong A, Mok C, Nowak AK, Lake RA and Lesterhuis WJ Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed? Lung Cancer Management 2014 3 (6) 443-457

2013

  • Lesterhuis, WJSalmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. PLoS One 2013 8(4) e61895
  • Creaney JC, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW and Robinson BWS Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? Lung Cancer 2013 80(1) 39-44
  • Cadby G, Mukherjee S, Musk AW, Reid A,Garlepp M, Dick I, Robinson C, Hui J, Fiorito G, Guarrera S, Beilby J, Meltona PE, Moses EK, Ugolini D, Mirabelli D, Bonassi S, Magnani C, Dianzani I, Matullo G, Robinson B, Creaney J, Palmer LJ A genome-wide association study for malignant mesothelioma risk Lung Cancer 2013 82(1) 44-8
  • Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BWS, Creaney J A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit Anatomical Pathology 2013 45(1) 1-8
  • Khong A, Brown MD, Vivian JB, Robinson BWS, Currie AJ Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model Journal of Immunotherapy 2013 36(7) 365-72
  • Creaney J, Dick IM, Segal A, Musk AW, Robinson BWS Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma Lung Cancer 2013 82(3) 491-498
  • Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A, Hirvonen A, Casalone E, Tunesi S, Padoan M, Giordano M, Aspesi A, Casadio C, Ardissone F, Ruffini E, Betta PG, Libener R, Guaschino R, Piccolini E, Neri M, Musk AW, de Klerk NH, Hui J, Beilby J, James AL, Creaney J, Robinson BW, Mukherjee S, Palmer LJ, Mirabelli D, Ugolini D, Bonassi S, Magnani C, Dianzani I Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study PLoS One 2013 8(4) e61253
  • Lustgarten DES, Deshpande C, Aggarwal C, Wang, L-C, Saloura V, Vachani A, Wang L-P, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G and Albelda, SM Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma Journal of Thoracic Oncology 2013 8(4) 469-77
  • Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PLR, Pavlakis N, Boyer M and Stockler MR A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma Lung Cancer 2013 81(3) 422-7
  • Brims FJ, Lee YCG and Creaney J The continual search for ideal biomarkers for mesothelioma: the hurdles Journal of Thoracic Disease 2013 5(3) 364-6
  • Labby ZE, Nowak AK, Dignam JJ, Straus C, Kindler HL, Armato SG 3rd Disease volumes as a marker for patient response in malignant pleural mesothelioma Ann Oncol 2013 24(4) 999-1005
  • McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies Cancer Immunol Immunother 2013 62(3) 529-39
  • Meniawy TM, Creaney J, Lake RA and Nowak AK Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma British Journal of Cancer 2013 109 1813-20
  • Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ and Robinson BWS Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum Disease Markers 2013 35(2) 119-27
  • Labby ZE, Armato SG 3rd, Dignam JJ, Straus C, Kindler HL, Nowak AK Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma Journal of Thoracic Oncology 2013 8(4) 478-86
  • Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study Lancet Oncol 2013 14(6) 543-51
  • Varano Della Vergiliana JF, Lansley S, Porcel JM, Bielsa S, Brown JS, Creaney J, Temple SEL, Waterer GW and Lee YCG Bacterial Infection Elicits Heat Shock Protein 72 Release from Pleural Mesothelial Cells PLoS ONE 2013 8(5) e63873
  • McCoy MJ, Nowak AK, Lake RA Activation of Immune-Mediated Tumor Cell Death by Chemotherapy Cell Death in Biology and Diseases 2013 Chp14 373-99
  • van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marshall H, Leong S, Keena V, Penman A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma Journal of Thoracic Disease 2013 Dec 5(6) E254-E307
  • Meniawy TM, Nowak AK and Lake RA; Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity; The Tumour Microenvironment; 2013; 5; 1-28

Back to top

2012

  • Hollevoet K, Reitsma JB, van Meerbeeck JP, Baas P, Creaney J, Cristaudo A, Di Serio F, Grigoriu D, Muley T, Nackaerts K, Pass HI, Rai AJ, Robinson BW, Rodriguez Portal JA, Scherpereel A, Schneider J, Tomasetti M; Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis; Journal of Clinical Oncology; 2012; 30(13); 1541-9
  • Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJB, Armstrong NJ, Vallely MP, Musk AW, Robinson BWS, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, and Reid G; Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma; Journal of Thoracic Oncology; 2012; 7(7); 1184-91
  • Park E-K, Yates DH, Creaney J, Thomas PS, Robinson BW, and Johnson AR; Association of Biomarker Levels with Severity of Asbestos-Related Diseases; Saf Health Work; 2012; 3(1); 17-21
  • Jackaman C, Lansley S, Allan JE, Robinson BWS and Nelson DJ; IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase; Int. Immunol.; 2012; 6; 357-68
  • Brown MD, van der Most R, Vivian JB, Lake RA, Larma I, Robinson BWS and Currie AJ; Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8+ T-cell immunity; Oncoimmunology; 2012; 1(7); 1-11
  • McDonnell AM, Currie AJ, Brown M, Kania K, Wylie B, Cleave Ar, Lake R and Robinson BWS; Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation; Oncoimmunology; 2012; 1(6); 1-7
  • Fisher S, Broomfield S, van Der Most R, Lake R, Robinson B and Currie A; Heat-Shocking of Murine Malignant Mesothelioma Cells Enhances Their Effectiveness as an Autologous Anti-Tumour Vaccine; Journal of Cancer Therapy; 2012; 3; 47-56
  • Robinson C, Woo S, Walsh A,Nowak AK and Lake RA; The Antioxidants Vitamins A and E and Selenium Do Not Reduce the Incidence of Asbestos-Induced Disease in a Mouse Model of Mesothelioma; Nutrition and Cancer; 2012; 64(2); 315-22
  • Jackaman C, Majewski D, Fox SA, Nowak AK and Nelson DJ; Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo; Cancer Immunology, Immunotherapy; 2012;
  • McCoy MJ, Lake RA, van der Most RG, Dick IM, and Nowak AK; Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies; British Journal of Cancer; 2012; 107; 1107-15
  • Khong A, Nelson DJ, Nowak AK, Lake RA and Robinson BWS; The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer; International Reviews of Immunology; 2012; 31(4); 246-66

Back to top

2011

  • Robinson B, Alatas MF, Robertson A, Steer H; Natural disasters and the lung.; Respirology.; 2011; 16(3); 1440-843
  • Bowyer S, Webb S, Millward M, Jasas K, Blacker D, Nowak A; Small cell lung cancer presenting with paraneoplastic limbic encephalitis.; Asia Pac J ClinOnco; 2011; 7(2); 180-4
  • Bagia M, Nowak AK; Novel targeted therapies and vaccination strategies for mesothelioma.; Curr Treat Options Oncol.; 2011; 12(2); 149-62
  • R; McDonnell AM, Nowak AK, Lake RA; Contribution of the immune system to the chemotherapeutic response; SeminImmunopathol.; 2011; 33(4); 353-67
  • Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M; The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.; Nat Genet; 2011; 43(7); 668-72
  • Robinson C, Walsh A, Larma I, O'Halloran S, Nowak AK, Lake RA; MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma.; Eur J Cancer; 2011; 47(1); 151-61
  • Varano Della Vergiliana JF, Lansley S, Tan AL, Creaney J, Lee YC, Stewart GA; Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation.; Biol Chem.; 2011; 392(7); 633-42
  • Boudville N, Paul R, Robinson BW, Creaney J; Mesothelin and kidney function-Analysis of relationship and implications for mesothelioma screening.; Lung Cancer; 2011; 73(3); 320-4
  • Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW; Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-Which is best?; Lung Cancer; 2011; 74(1); 55-60
  • Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK; Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.; Clin Cancer Res.; 2011; 17(5); 1181-9
  • Robinson C, Walsh A, Larma I, O'Halloran S, Nowak AK, Lake RA. MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma European Journal Of Cancer; 2011; 47(1); 151-61
  • McDonnell A, Nowak AK, Lake RA; Contribution of the immune system to the chemotherapeutic response; Seminars in Immunopathology; 2011; 33(4); 353-67
  • Creaney J, Dick IM, Yeoman D, Wong S, Robinson BWS; Auto-Antibodies to ?-F1-ATPase and Vimentin in Malignant Mesothelioma; PLoS ONE; 2011; 6(10);
  • R; Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BWS, Rusch VW, Sugarbaker DJ, van Zandwijk N; The MARS feasibility trial: conclusions not supported by data; The Lancet Oncology; 2011; 12(12); 1093-4
  • Lesterhuis, WJ, Steer, H. and Lake RA; PD-L2 is predominantly expressed by Th2 cells; Molecular Immunology; 2011; 49(1-2); 1-3
  • Gerbaudo VH, Kat, SI, Nowa, AK, and Franci, RJ; Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging; PET Clinics; 2011; 6(3); 275-97
  • Nowak AK, Francis, RJ, Katz, SI and Gerbaudo, VH; A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment; PET Clinics; 2011; 6(3); 299-311
  • Eastwood PR, Naughton MT, Calverley P, Zeng G, Beasley R, Robinson B and Lee YC; Natural disasters and the lung; Respirology.; 2011; 17; 792-801
  • Tung A, Bilaceroglu S, Porcel JM, Creaney J, and Lee YCG; Biomarkers in Pleural Diseases; US Respiratory Disease; 2011; 7(1); 26-31
  • H J Steer, A Cleaver, A Nowak, B Robinson, R Lake; S59 Chemo-immunotherapy of mesothelioma: depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model; Thorax; 2011; 66; A29

Back to top

2010

  • Nowak AK, Armato SG, Ceresoli GL, Yildirim H, Francis RJ; Imaging in Pleural Mesothelioma: A Review of Imaging Research presented at the 9th International Meeting of the International Mesothelioma Interest Group; Lung Cancer; 2010; 70(1); 1-6
  • McDonnell AM, Prosser AC, van Bruggen I, Robinson BWS, Currie AJ; CD8?+ DCs are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor; European Journal of Immunology; 2010; 40(6); 1617-27
  • Kurts, C, Robinson BWS, Knolle PA; Cross-priming in health and disease; Nature Reviews Immunology; 2010; 10(6); 403-14
  • Creaney J, Musk AW, Robinson BW; Sensitivity of urinary mesothelin in patients with malignant mesothelioma.J ThoracOncol.; 2010; 5(9); 1461-6
  • Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW; Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.; Cancer Epidemiol Biomarkers Prev.; 2010; 19(9); 2238-46
  • R; Steer HJ, Lake RA, Nowak AK, Robinson BW; Harnessing the immune response to treat cancer.Oncogene.; 2010; 29; 6301-13
  • McDonnell AM, Robinson BW, Currie AJ; Tumour antigen cross-presentation and the dendritic cell: where it all begins?; ClinDevImmunol.; 2010; 539519
  • Blinman P, McLachlan SA, Nowak AK, Duric VM, Brown C, Wright G, Millward M, Fong K, Stockler MR.; Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile?; Lung Cancer; 2010; 72(2); 213-8
  • Hasani A, Feeney K, Nowak AK, Millward M. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia; Asia Pacific Journal of Clinical Oncology; 2010; 6(4); 350-6
  • Nowak AK, Francis RJ, Phillips M, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, and Byrne MJ; A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters Clinical Cancer Research; 2010; 16; 2409-17

Back to top

2009

  • Jackaman C, Cornwall S, Robinson BWS, Lew AM, Zhan Y, Nelson DJ; Local effector failure in mesothelioma is not mediated by CD4+CD25+Treg cells.; European Respiratory Journal; 2009; 34(1); 162-75
  • van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA; Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.; Cancer ImmunolImmunother; 2009; 58(8); 1219-28
  • R; Creaney J and Robinson BWS; Serum and pleural fluid biomarkers for mesothelioma.; Current Opinion in Pulmonary Medicine; 2009; 15(4); 366-70
  • Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG; Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.; J Immunol; 2009; 183(12); 7898-908
  • van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA; Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.; PLoS One; 2009; 4(9); e6982
  • Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ; Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.; J Immunol.; 2009; 182(9); 5217-24
  • Nowak AK; Radiographic Measurement of Tumour Load in Pleural Malignancies; International Pleural Newsletter2009; 7(3); 2-3
  • Hasani A, Alvarez JM, Ma Wyatt J, Bydder S, Millward M, Byrne M, Musk AW, Nowak AK; Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia; Journal of Thoracic Oncology; 2009; 4(8); 1010-6
  • Hasani A, Nowak AK; Current management of Malignant Pleural Mesothelioma; Asia Pacific Journal of Oncology and Haematology; 2009; 1(1); 1-11
  • R; McCoy M, Nowak AK, Lake RA; Chemo-immunotherapy - an emerging strategy for the treatment of malignant mesothelioma; Tissue Antigens; 2009; 74(1); 1-10

Back to top

2008

  • R; Van der Most RG, Currie AJ, Robinson BW, Lake RA; Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.; Cell Death Differ.; 2008; 15(1); 13-20
  • Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ; Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.; Br J Cancer.; 2008; 98(9); 1562-9
  • Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. 2008 Feb 1; 180(3):1535-44; Targeting the Effector Site with IFN-{alpha}{beta}-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors.; J Immunol.; 2008; 180(3); 1535-44
  • Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR; Soluble mesothelin-related protein in an asbestos-exposed population: the dust-diseases board cohort study; Am J RespirCrit Care Med.; 2008; 178(8); 832-7
  • Creaney J, Yeoman, D, Demelker, Y, Segal A, Musk, AW, Skates, SJ, Robinson BWS; Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma.; Journal of Thoracic Oncology; 2008; 3(8); 851-7
  • Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ; Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.; IntImmunol.; 2008; 20(11); 1467-79
  • R; Haynes NM, van der Most RG, Lake RA and Smyth MJ; Immunogenic anti-cancer chemotherapy as an emerging concept; Current Opinion in Immunology 2008; 20(5); 545-57
  • Armato S, Entwistle M, Truong M, Nowak AK, Ceresoli , Zhao B, Misri R, Kindler H; Current state and future directions of pleural mesothelioma imaging Lung Cancer; 2008; 59(3); 411-20
  • Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K; Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.; Lung Cancer; 2008; 61(2); 235-43

Back to top

2007

  • Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand M-C, Kjaerheim K, Pass HI, Robinson BWS, Tsao A; Outcomes from the Eighth International Mesothelioma Conference; Oncogene; 2007; 26(49); 6959-67
  • Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BWS; Soluble mesothelin in effusions - a useful tool for the diagnosis of malignant mesothelioma.; Thorax; 2007; 62(7); 569-76
  • Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW; Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.; Chest; 2007; 132(4); 1239-46
  • Roslyn J Francis, Michael J Byrne, Agatha A van der Schaaf, Jan A Boucek, Anna K Nowak, Michael Phillips, Richard Price, Andrew P Patrikeos, A William Musk, Michael J Millward; Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma using a Novel Semi-automated 3D Volume-Based Analysis of Serial FDG PET scans; Journal of Nuclear Medicine; 2007; 48; 1449-58
  • R; Nowak AK, Bydder S; Management of Malignant Pleural Mesothelioma: a review; Asia Pacific Journal of Clinical Oncology; 2007; 3(4); 177-86
  • Hunter C, LaMontagne A; "Investigating 'Community' through a History of Responses to Asbestos-Related Disease in an Australian Industrial Region."; Social History of Medicine; 2007; 21(2); 361-79
  • Reid A, Heyworth J, de Klerk NH, Musk AW; The mortality of women exposed to blue asbestos at Wittenoom, Western Australia.; Occupational and Environmental Medicine; 2007; 65(11); 743-9
  • Reid A, Heyworth J, de Klerk NH, Musk AW; Cancer Incidence among women and girls environmentally and occupationally exposed to blue asbestos at Wittenoom, Western Australia.; International Journal of Cancer; 2007; 122(10); 2337-44

Back to top

 

National Centre for Asbestos Related Diseases

This Page

Last updated:
Thursday, 3 December, 2015 10:28 AM

http://www.ncard.uwa.edu.au/2636400